Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

Graves’ orbitopathy (GO) is the most common extrathyroidal manifestation of Graves’ disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label multicenter study of glucocorticoid-resistant GO treated with TCZ. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Bilbao, Lara, Martínez-López, David, Revenga, Marcelino, López-Vázquez, Ángel, Valls-Pascual, Elia, Atienza-Mateo, Belén, Valls-Espinosa, Beatriz, Maiz-Alonso, Olga, Blanco, Ana, Torre-Salaberri, Ignacio, Rodríguez-Méndez, Verónica, García-Aparicio, Ángel, Veroz-González, Raúl, Jovaní, Vega, Peiteado, Diana, Sánchez-Orgaz, Margarita, Tomero, Eva, Toyos-Sáenz de Miera, Francisco J., Pinillos, Valvanera, Aurrecoechea, Elena, Mora, Ángel, Conesa, Arantxa, Fernández-Prada, Manuel, Troyano, Juan A., Calvo-Río, Vanesa, Demetrio-Pablo, Rosalía, González-Mazón, Íñigo, Hernández, José L., Castañeda, Santos, González-Gay, Miguel Á., Blanco, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563792/
https://www.ncbi.nlm.nih.gov/pubmed/32878150
http://dx.doi.org/10.3390/jcm9092816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563792/
https://www.ncbi.nlm.nih.gov/pubmed/32878150
http://dx.doi.org/10.3390/jcm9092816

Ejemplares similares